QualityDipStocks / Health Care · Pharmaceuticals
Amylyx Pharmaceuticals AMLX
Outside our quality screen, so we don’t track its dips. It’s 29% below its 52-week high.
Outside our quality screen, 5% under its Market Value. No fair value estimate for now: its free cash flow is negative.
- Fair value est.
- n/a
- Market Value
- $29.57price −5%
- Off 52-wk high
- −29%
- Risk vs market
- Market-likebeta 0.93
3 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for AMLX: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much AMLX moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 6.8× the S&P 500’s.
- Beta vs S&P 500
- 0.93
- Volatility
- 87% vs 13% SPY
- Correlation SPY
- 0.14
- Correlation QQQ
- 0.09
Valuation details
MV $29.57
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
ProfitabilityOperating margin widened to 10.2% in FY2023 from −535.3% in FY2022 (SEC filings).
ProfitabilityGross margin widened to 93.2% in FY2024 from 86.5% in FY2022 (SEC filings).
ValuationTrades 5.2% below its Market Value of $29.57, the average price paid since the Sep 8 filing.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$127M over the last 12 months), so there’s no cash-flow value under the price.
GrowthSales fell 100% over the last 12 months vs the 12 months before (SEC filings).
ProfitabilityLost $145M over the last 12 months (net income, SEC filings).
ProfitabilityReturn on equity fell 59 points in two fiscal years, to -47% in FY2025.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
All fundamentals
FCF yield -3.5% · ROE -62% · Sales −100%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −3.5%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- n/anot reported in its SEC filings
- Price / book
- 11.47×
- Market cap
- $3.5Blisted
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $0
- Sales growth, 12 months
- −100.0%vs the 12 months before
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- −$1.53
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$145M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- n/anot reported in its SEC filings
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- −62%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $317M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- −$123M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +24.7%diluted shares vs a year ago
- Stock-based comp
- $28M
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Amylyx Pharmaceuticals’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.1B
- Free cash flow, 12 months−$0.1B
- Free-cash-flow yield-3.5%
- Gross margin0%
- Operating margin0%
- Return on equity−75%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $28.04
- 52-wk lowlowest close, 1 year$11.38−59.4%
- PriceMon Nov 2 close$28.04you are here
- Market Valueavg paid since Sep 8$29.57+5.5%
- 52-wk highhighest close, 1 year$39.66+41.4%
Momentum & 52-week range
RSI 47 · 5 days +3.5%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 5
- DateThu Nov 5, before the open
- Consensus EPS($0.38)
- Year-ago EPS($0.37)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
AMLX is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Amylyx Pharmaceuticals in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.